GRCE Grace Therapeutics, Inc.
Healthcare$2.36+7.27%ClosedMarket Cap: $36.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.57
P/S
0.00
EV/EBITDA
-0.98
DCF Value
$1.30
FCF Yield
-29.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-12.7%
ROA
-11.9%
ROIC
-19.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 null | $0.00 | NaN% | $-3.4M | $-3.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-3.5M | $-1.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-4.2M | $-4.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-4.5M | $905.7K | $— | — |
| FY null | $0.00 | NaN% | $-23.8M | $-13.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-5.3M | $-6.0M | $— | — |
| Q2 null | $0.00 | NaN% | $-6.6M | $-4.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-6.8M | $-3.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-4.4M | $-4.3M | $— | — |
| FY null | $0.00 | NaN% | $-17.4M | $-17.4M | $— | — |
| Q3 2024 | $0.00 | NaN% | $-3.0M | $-2.4M | $-0.32 | — |
| Q2 2024 | $0.00 | -Infinity% | $-2.1M | $-3.3M | $-0.43 | — |